603087: Gan & Lee Pharmaceuticals. - Summary | Jitta

Gan & Lee Pharmaceuticals.

CHN:603087

Price
CN¥70.38
Loss Chance
42.4%
6.09JITTA SCORE
29.45%Over Jitta Line
Jitta Ranking
18 / 486
239 / 5,278
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (72)
Recent Business Performance (87)
Financial Strength (75)
Return to Shareholders (21)
Competitive Advantage (62)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Revenue and EarningEarning loss detected in 2022
Operating MarginInconsistent
Cash Conversion CycleMore than 1 year
Key Stats
Jitta Score
Jitta Line
6.09
29.45%
3.62
> 1,000%
4.26
> 1,000%
Biotechnology
6.69
91.21%
7.64
8.97%
5.95
321.28%
COMPANY DESCRIPTION
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insulin pen needle. The company was formerly known as Beijing Gan & Lee Biotechnology Co., Ltd. and changed its name to Gan & Lee Pharmaceuticals. in April 2005. Gan & Lee Pharmaceuticals. was founded in 1998 and is headquartered in Beijing, the People’s Republic of China.